Derma Sciences skins out $36M

December 12, 2012 by MassDevice staff

Derma Sciences raises $36 million closes a $36 million public stock offering it plans to use to continue development on its lead drug candidate for diabetic foot ulcers.

Derma Sciences

Derma Sciences (NSDQ:DSCI) said it's closed an offering of some 3.5 million shares of its stock at $10.34 apiece.

The Princeton, N.J.-based medical device company said it plans to use the $33.8 million in net proceeds from the $36.4 million offering to further develop its lead drug candidate DSC127.

Derma Sciences said the drug is being designed to treat chronic diabetic foot ulcers.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.